A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma
This is the case of a 68-year-old male. On the 14th day after the introduction of atezolizumab, an immune-checkpoint inhibitor (ICI) for hepatocellular carcinoma, the patient developed difficulty in moving and had chills. Since body temperature was 39.4°C, consciousness disorder developed on the 16t...
Gespeichert in:
| Veröffentlicht in: | Kanzo 2021/09/01, Vol.62(9), pp.590-592 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 592 |
|---|---|
| container_issue | 9 |
| container_start_page | 590 |
| container_title | Kanzo |
| container_volume | 62 |
| creator | Hirata, Taiki Sugimoto, Katsutoshi Kakegawa, Tatsuya Takahashi, Hiroshi Tomita, Yusuke Wada, Takuya Abe, Masakazu Yoshimasu, Yu Takeuchi, Hirohito Saito, Kazuhiro Terashi, Hiroo Itoi, Takao |
| description | This is the case of a 68-year-old male. On the 14th day after the introduction of atezolizumab, an immune-checkpoint inhibitor (ICI) for hepatocellular carcinoma, the patient developed difficulty in moving and had chills. Since body temperature was 39.4°C, consciousness disorder developed on the 16th day, and steroid pulse therapy was started for possible encephalitis, which is an immune-related adverse event (irAE) caused by atezolizumab, steroid administration was continued because the patient's consciousness disorder improved, and no relapse of symptoms was observed. Listing irAEs as a differentiation of fever and impaired consciousness of unknown cause during ICI administration and starting treatment as soon as possible are important. |
| doi_str_mv | 10.2957/kanzo.62.590 |
| format | Article |
| fullrecord | <record><control><sourceid>jstage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2957_kanzo_62_590</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>article_kanzo_62_9_62_590_article_char_en</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2440-e78e832fd6b1e901a3104c1b83b99e9fe82565c552882192683d2cbc7dbe216d3</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRsNTe_AF719T9SNLdk5TiFxS86DlMNhOzmmTD7kZo7_5vW1vqaXiZ552Bh5BrzuZCZ4u7L-i3bp6LeabZGZlwpXgiMy3PyYSlGU9SweQlmYVgS8ZEvmBaiwn5WVIDAamraRjDgCZiRWGMznbd2CPF3uDQQGujDRTqiJ7GBqnto3fVaKJ1_b4LEbeutduxg5Le0BK_wRzTDvcwbGjtPG1wgOgMtu3Ygt999sb2roMrclFDG3B2nFPy_vjwtnpO1q9PL6vlOjEiTVmCC4VKirrKS46acZCcpYaXSpZao65RiSzPTJYJpQTXIleyEqY0i6pEwfNKTsnt4a7xLgSPdTF424HfFJwVe4vFn8UiF8XO4g6_P-CfIcIHnmDw0ZoW_2F9bJw2pgFfYC9_ASBEgQo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma</title><source>J-STAGE Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hirata, Taiki ; Sugimoto, Katsutoshi ; Kakegawa, Tatsuya ; Takahashi, Hiroshi ; Tomita, Yusuke ; Wada, Takuya ; Abe, Masakazu ; Yoshimasu, Yu ; Takeuchi, Hirohito ; Saito, Kazuhiro ; Terashi, Hiroo ; Itoi, Takao</creator><creatorcontrib>Hirata, Taiki ; Sugimoto, Katsutoshi ; Kakegawa, Tatsuya ; Takahashi, Hiroshi ; Tomita, Yusuke ; Wada, Takuya ; Abe, Masakazu ; Yoshimasu, Yu ; Takeuchi, Hirohito ; Saito, Kazuhiro ; Terashi, Hiroo ; Itoi, Takao</creatorcontrib><description>This is the case of a 68-year-old male. On the 14th day after the introduction of atezolizumab, an immune-checkpoint inhibitor (ICI) for hepatocellular carcinoma, the patient developed difficulty in moving and had chills. Since body temperature was 39.4°C, consciousness disorder developed on the 16th day, and steroid pulse therapy was started for possible encephalitis, which is an immune-related adverse event (irAE) caused by atezolizumab, steroid administration was continued because the patient's consciousness disorder improved, and no relapse of symptoms was observed. Listing irAEs as a differentiation of fever and impaired consciousness of unknown cause during ICI administration and starting treatment as soon as possible are important.</description><identifier>ISSN: 0451-4203</identifier><identifier>EISSN: 1881-3593</identifier><identifier>DOI: 10.2957/kanzo.62.590</identifier><language>eng ; jpn</language><publisher>The Japan Society of Hepatology</publisher><subject>atezolizumab ; encephalitis ; immune-related adverse events</subject><ispartof>Kanzo, 2021/09/01, Vol.62(9), pp.590-592</ispartof><rights>2021 The Japan Society of Hepatology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2440-e78e832fd6b1e901a3104c1b83b99e9fe82565c552882192683d2cbc7dbe216d3</citedby><cites>FETCH-LOGICAL-c2440-e78e832fd6b1e901a3104c1b83b99e9fe82565c552882192683d2cbc7dbe216d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1876,27903,27904</link.rule.ids></links><search><creatorcontrib>Hirata, Taiki</creatorcontrib><creatorcontrib>Sugimoto, Katsutoshi</creatorcontrib><creatorcontrib>Kakegawa, Tatsuya</creatorcontrib><creatorcontrib>Takahashi, Hiroshi</creatorcontrib><creatorcontrib>Tomita, Yusuke</creatorcontrib><creatorcontrib>Wada, Takuya</creatorcontrib><creatorcontrib>Abe, Masakazu</creatorcontrib><creatorcontrib>Yoshimasu, Yu</creatorcontrib><creatorcontrib>Takeuchi, Hirohito</creatorcontrib><creatorcontrib>Saito, Kazuhiro</creatorcontrib><creatorcontrib>Terashi, Hiroo</creatorcontrib><creatorcontrib>Itoi, Takao</creatorcontrib><title>A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma</title><title>Kanzo</title><addtitle>Kanzo</addtitle><description>This is the case of a 68-year-old male. On the 14th day after the introduction of atezolizumab, an immune-checkpoint inhibitor (ICI) for hepatocellular carcinoma, the patient developed difficulty in moving and had chills. Since body temperature was 39.4°C, consciousness disorder developed on the 16th day, and steroid pulse therapy was started for possible encephalitis, which is an immune-related adverse event (irAE) caused by atezolizumab, steroid administration was continued because the patient's consciousness disorder improved, and no relapse of symptoms was observed. Listing irAEs as a differentiation of fever and impaired consciousness of unknown cause during ICI administration and starting treatment as soon as possible are important.</description><subject>atezolizumab</subject><subject>encephalitis</subject><subject>immune-related adverse events</subject><issn>0451-4203</issn><issn>1881-3593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpFkE1Lw0AQhhdRsNTe_AF719T9SNLdk5TiFxS86DlMNhOzmmTD7kZo7_5vW1vqaXiZ552Bh5BrzuZCZ4u7L-i3bp6LeabZGZlwpXgiMy3PyYSlGU9SweQlmYVgS8ZEvmBaiwn5WVIDAamraRjDgCZiRWGMznbd2CPF3uDQQGujDRTqiJ7GBqnto3fVaKJ1_b4LEbeutduxg5Le0BK_wRzTDvcwbGjtPG1wgOgMtu3Ygt999sb2roMrclFDG3B2nFPy_vjwtnpO1q9PL6vlOjEiTVmCC4VKirrKS46acZCcpYaXSpZao65RiSzPTJYJpQTXIleyEqY0i6pEwfNKTsnt4a7xLgSPdTF424HfFJwVe4vFn8UiF8XO4g6_P-CfIcIHnmDw0ZoW_2F9bJw2pgFfYC9_ASBEgQo</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Hirata, Taiki</creator><creator>Sugimoto, Katsutoshi</creator><creator>Kakegawa, Tatsuya</creator><creator>Takahashi, Hiroshi</creator><creator>Tomita, Yusuke</creator><creator>Wada, Takuya</creator><creator>Abe, Masakazu</creator><creator>Yoshimasu, Yu</creator><creator>Takeuchi, Hirohito</creator><creator>Saito, Kazuhiro</creator><creator>Terashi, Hiroo</creator><creator>Itoi, Takao</creator><general>The Japan Society of Hepatology</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20210901</creationdate><title>A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma</title><author>Hirata, Taiki ; Sugimoto, Katsutoshi ; Kakegawa, Tatsuya ; Takahashi, Hiroshi ; Tomita, Yusuke ; Wada, Takuya ; Abe, Masakazu ; Yoshimasu, Yu ; Takeuchi, Hirohito ; Saito, Kazuhiro ; Terashi, Hiroo ; Itoi, Takao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2440-e78e832fd6b1e901a3104c1b83b99e9fe82565c552882192683d2cbc7dbe216d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>2021</creationdate><topic>atezolizumab</topic><topic>encephalitis</topic><topic>immune-related adverse events</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirata, Taiki</creatorcontrib><creatorcontrib>Sugimoto, Katsutoshi</creatorcontrib><creatorcontrib>Kakegawa, Tatsuya</creatorcontrib><creatorcontrib>Takahashi, Hiroshi</creatorcontrib><creatorcontrib>Tomita, Yusuke</creatorcontrib><creatorcontrib>Wada, Takuya</creatorcontrib><creatorcontrib>Abe, Masakazu</creatorcontrib><creatorcontrib>Yoshimasu, Yu</creatorcontrib><creatorcontrib>Takeuchi, Hirohito</creatorcontrib><creatorcontrib>Saito, Kazuhiro</creatorcontrib><creatorcontrib>Terashi, Hiroo</creatorcontrib><creatorcontrib>Itoi, Takao</creatorcontrib><collection>CrossRef</collection><jtitle>Kanzo</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirata, Taiki</au><au>Sugimoto, Katsutoshi</au><au>Kakegawa, Tatsuya</au><au>Takahashi, Hiroshi</au><au>Tomita, Yusuke</au><au>Wada, Takuya</au><au>Abe, Masakazu</au><au>Yoshimasu, Yu</au><au>Takeuchi, Hirohito</au><au>Saito, Kazuhiro</au><au>Terashi, Hiroo</au><au>Itoi, Takao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma</atitle><jtitle>Kanzo</jtitle><addtitle>Kanzo</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>62</volume><issue>9</issue><spage>590</spage><epage>592</epage><pages>590-592</pages><issn>0451-4203</issn><eissn>1881-3593</eissn><abstract>This is the case of a 68-year-old male. On the 14th day after the introduction of atezolizumab, an immune-checkpoint inhibitor (ICI) for hepatocellular carcinoma, the patient developed difficulty in moving and had chills. Since body temperature was 39.4°C, consciousness disorder developed on the 16th day, and steroid pulse therapy was started for possible encephalitis, which is an immune-related adverse event (irAE) caused by atezolizumab, steroid administration was continued because the patient's consciousness disorder improved, and no relapse of symptoms was observed. Listing irAEs as a differentiation of fever and impaired consciousness of unknown cause during ICI administration and starting treatment as soon as possible are important.</abstract><pub>The Japan Society of Hepatology</pub><doi>10.2957/kanzo.62.590</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0451-4203 |
| ispartof | Kanzo, 2021/09/01, Vol.62(9), pp.590-592 |
| issn | 0451-4203 1881-3593 |
| language | eng ; jpn |
| recordid | cdi_crossref_primary_10_2957_kanzo_62_590 |
| source | J-STAGE Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | atezolizumab encephalitis immune-related adverse events |
| title | A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T14%3A18%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20of%20suspected%20autoimmune%20encephalitis%20after%20the%20introduction%20of%20atezolizumab%20+%20bevacizumab%20therapy%20for%20hepatocellular%20carcinoma&rft.jtitle=Kanzo&rft.au=Hirata,%20Taiki&rft.date=2021-09-01&rft.volume=62&rft.issue=9&rft.spage=590&rft.epage=592&rft.pages=590-592&rft.issn=0451-4203&rft.eissn=1881-3593&rft_id=info:doi/10.2957/kanzo.62.590&rft_dat=%3Cjstage_cross%3Earticle_kanzo_62_9_62_590_article_char_en%3C/jstage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |